Table 1.
Overall patient characteristics and for COVID-19 cases in PLwMS treated with ocrelizumab at Maccabi Health Services.
| Characteristic | Ocrelizumab cohort All patients (n = 269) | Ocrelizumab cohort COVID-19 cases (n = 29) |
|---|---|---|
| Female sex | 154 (57.2%) | 16 (55.2%) |
| Age (years) | ||
| Mean (SD) | 50.8 (11.7) | 49.4 (11.9) |
| MS subtype* | ||
| Relapsing-remitting MS | 104 (38.7%) | 10 (34.5%) |
| Primary progressive MS | 95 (35.3%) | 11(37.9%) |
| Progressive form (unspecified) | 45 (16.7%) | 6 (20.7%) |
| MS general (unspecified) | 25 (9.3%) | 2 (6.9%) |
| MS disease duration (years) | ||
| Mean (SD) | 12.0 (6.8) | 12.2 (7.2) |
| Ocrelizumab exposure time (years) | ||
| Mean (SD) | 2.0 (0.3) | 2.0 (0.4) |
| Underlying conditions | ||
| Current cancer or history of cancer | 14 (5.2%) | 1 (3.4%) |
| Moderate liver disease | 31 (11.5%) | 3 (10.3%) |
| Hemiplegia/paraplegia | 35 (13.0% | 4 (13.8%) |
| Dementia | 18 (6.7%) | 1 (3.4%) |
| Cardiovascular disease | 16 (5.9%) | 4 (13.8%) |
| Hypertension | 55 (20.4%) | 9 (31.0%) |
| Diabetes | 17 (6.3%) | 4 (13.8%) |
| COPD | 21 (7.8%) | 2 (6.9%) |
| Chronic kidney disease | 23 (8.6%) | 4 (13.8%) |
| COVID-19 outcomesa | ||
| All cases | NA | 29 |
| Mild/moderate (non-hospitalized) | 20 (69.9%) | |
| Severe (Hospitalized/ICU/death) | 9 (31.0%) | |
| Hospitalized | 5 (17.2%) | |
| ICU admission | 3 (10.3%) | |
| Death | 1 (3.4%) | |
| Pre-vaccination era/partially vaccinated | NA | 21 |
| Mild/moderate (non-hospitalized) | 14 (66.7%) | |
| Severe (Hospitalized/ICU/death) | 7 (33.3%) | |
| Hospitalized | 3 (14.3%) | |
| ICU admission | 3 (14.3%) | |
| Death | 1 (4.8%) | |
| Fully vaccinated | NA | 8 |
| Mild/moderate (non-hospitalized) | 6 (75.0%) | |
| Severe (Hospitalized/ICU/death) | 2 (25.0%) | |
| Hospitalized | 2 (25.0%) | |
| ICU admission | 0 | |
| Death | 0 |
COPD,chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; ICU, intensive care unit; MS, multiple sclerosis; PLwMS, patients living with multiple sclerosis; SD, standard deviation; NA, not applicable.
Categories are mutually exclusive and based on recorded worse outcome by patient (i.e., death > ICU > hospitalization > non hospitalized).
Based on Maccabi Health Services specific codes for MS subtypes (i.e., Y12601 Multiple sclerosis, Y21012 Multiple Sclerosis Remitting Relapsing, Y21013 Multiple Sclerosis Progressive Form, Y21014 Multiple sclerosis Progressive Primary, Multiple Sclerosis Progressive Secondary).